Market
Will Senti Biosciences secure additional financing by the end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Senti Biosciences official announcements or financial news outlets
Story
Senti Biosciences Reports Positive SENTI-202 Trial Data, Secures $37.6M Financing, and Sees 139.8% Stock Increase
Dec 2, 2024, 01:20 PM
Senti Biosciences, Inc. announced positive initial clinical data from its Phase 1 trial of SENTI-202, a logic-gated, selective CD33/FLT3-targeting CAR-NK cell therapy for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The trial showed promising results, with two out of three patients achieving minimal residual disease (MRD)-negative complete remission (CR) and a generally favorable safety profile. Additionally, the company secured $37.6 million in an oversubscribed private placement equity financing and appointed Fran Schulz to its Board of Directors as a new member and audit chair. These developments have led to a significant pre-market stock price increase of 139.8%.
View original story
Similar markets
Yes • 50%
No • 50%
Less than $50 million • 25%
$100 million to $200 million • 25%
$50 million to $100 million • 25%
More than $200 million • 25%
Above $15B • 25%
$10.2B to $15B • 25%
$5B to $10.2B • 25%
Below $5B • 25%
More than $300 million • 25%
$100 million to $200 million • 25%
Less than $100 million • 25%
$200 million to $300 million • 25%
$25 billion • 25%
$15 billion • 25%
Other • 25%
$20 billion • 25%
